ウイルスベクター・プラスミドDNA製造の市場規模、シェア、動向分析レポート：ベクタータイプ別、ワークフロー別、用途別、最終用途別、疾患別、地域別、セグメント別予測、2024年～2030年

ウイルスベクター・プラスミドDNA製造市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のウイルスベクター・プラスミドDNA製造市場規模は、2030年までに195億米ドルに達すると予測され、2024年から2030年までのCAGRは20.2%で成長すると予測されています。

遺伝子治療用のプラスミドDNAやウイルスベクターの需要が高まる中、業界のリーダーたちはプラスミドDNA製造を後押しする新技術を発表しています。例えば、2018年4月、GEヘルスケア・ライフサイエンスは、ウイルスベクターに基づくオンコリティックウイルス、細胞・遺伝子治療、免疫の製造のためのプレハブ型モジュール式バイオプロセス施設であるKUBio BSL 2を発表しました。

細胞・遺伝子治療研究分野への投資の増加に伴い、市場ではウイルスベクターに対するこれまでにない需要が生じています。このため、さまざまな組織がこれらのベクターの製造プロセスの開発を加速するための資金を提供しています。例えば、2019年9月、Next Generation Manufacturing Canadaは、iVexSol Canadaが率いるコンソーシアムに189万米ドルを提供しました。この資金は、レンチウイルスベクターの高度な製造プロセスの開発のために提供されました。2iVexSolカナダはベクター製造会社で、複数の企業と協力して先進的なLVV製造プラットフォームを開発しています。

さらに、サーモフィッシャーサイエンティフィック、QIAGEN NV、アジレント・テクノロジー、タカラバイオ、オックスフォード・バイオメディカなど、この市場で事業を展開する主要企業は、新しい遺伝子導入プラットフォームの開発に注力しています。これらの企業は、市場の需要増に対応するため、生物学的遺伝子導入システムの生産規模を拡大するために巨額の投資を行っています。例えば、タカラバイオは2020年5月、滋賀県に遺伝子・細胞治療プロセッシングIIセンター（CGCPII）の建設を完了しました。このセンターは同社のGMPウイルスベクター生産施設に追加されるものです。同様に、サーモフィッシャーサイエンティフィック社も2020年5月に1億8,000万米ドルを投資し、ウイルスベクター製造能力を2倍に拡大しました。このようなイニシアチブの増加は、予測期間中の市場成長を促進すると予想されます。

さらに、ウイルスベクターの大量生産は、上流工程と下流工程で課題に直面しています。上流工程では、ウイルスベクター製造に使用される方法がメーカーにとって大きなハードルの一つとなっています。接着細胞培養を大規模に再現することは、対処すべき重要な懸念事項です。そのため、研究者たちは大型バイオリアクターを使ってこれらの細胞を培養しようとしています。さらに、下流工程におけるこれらのベクターの純度についての理解を深める必要があります。

ウイルスベクター・プラスミドDNA製造市場レポートハイライト：

• ベクタータイプに基づくと、アデノ随伴ウイルス（AAV）セグメントは高い需要により2023年の売上高シェア20.0%で市場を独占し、臨床試験での利用が拡大しています。
• ワークフローに基づくと、下流処理技術の進歩とシングルユースシステムの採用により、2023年には下流処理分野がワークフロー分野で最大の収益シェアを占め、市場をリードしました。
• 用途別では、2023年にワクチン療法分野が最大の収益シェアで市場を独占し、予測期間中に細胞療法が最も速いCAGRで成長すると予測されています。
• 最終用途別では、研究機関セグメントが2023年に最大の収益シェアで市場を独占しました。一方、製薬会社およびバイオ製薬会社は予測期間中に最も速いCAGRで成長すると予測されています。
• 疾患別では、がん分野が2023年に最大の収益シェアで市場を独占し、予測期間中に最も速いCAGRで成長すると予測されます。
• 北米は、がんや感染症の負担が大きいこと、購買力平価が高いこと、質の高いヘルスケアに対する政府の支援があること、償還が可能であることなどの要因により、市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ウイルスベクター・プラスミドDNA製造市場の変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ウイルスベクター・プラスミドDNA製造市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 ウイルスベクター・プラスミドDNA製造市場：ベクタータイプの推定・動向分析

• ベクタータイプ別の世界のウイルスベクター・プラスミドDNA製造市場の見通し
• アデノ随伴ウイルス（AAV）
• レンチウイルス
• アデノウイルス
• レトロウイルス
• プラスミド
• その他

第5章 ウイルスベクター・プラスミドDNA製造市場：ワークフローの推定・動向分析

• ワークフロー別の世界のウイルスベクター・プラスミドDNA製造市場の見通し
• 上流処理
• 下流処理

第6章 ウイルスベクター・プラスミドDNA製造市場：用途の推定・動向分析

• 用途別の世界のウイルスベクター・プラスミドDNA製造市場の見通し
• 遺伝子治療
• 細胞治療
• ワクチン
• 研究用途

第7章 ウイルスベクター・プラスミドDNA製造市場：最終用途の推定・動向分析

• 最終用途別の世界のウイルスベクター・プラスミドDNA製造市場の見通し
• 製薬企業・バイオ医薬品企業
• 研究機関

第8章 ウイルスベクター・プラスミドDNA製造市場：疾患の推定・動向分析

• 疾患別の世界のウイルスベクター・プラスミドDNA製造市場の見通し
• がん
• 遺伝性疾患
• 感染症
• その他

第9章 ウイルスベクター・プラスミドDNA製造市場：地域の推定・動向分析

• 地域の市場シェア分析、2023年および2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 企業の分類
• 戦略マッピング
• 企業の市況分析、2023年
• 企業プロファイル・一覧表
  • Merck KGaA
  • Lonza
  • FUJIFILM Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent Inc.
  • Wuxi Biologics
  • Takara Bio Inc.
  • Waisman Biomanufacturing
  • Genezen laboratories
  • Batavia Biosciences
  • Miltenyi Biotec GmbH
  • SIRION Biotech GmbH
  • Virovek Incorporation
  • BioNTech IMFS GmbH
  • Audentes Therapeutics
  • BioMarin Pharmaceutical
  • RegenxBio, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
• Table 3 North America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 4 North America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 5 North America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 6 North America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 7 North America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 8 U.S. viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 9 U.S. viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 10 U.S. viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 11 U.S. viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 12 U.S. viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 13 Canada viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 14 Canada viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 15 Canada viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 16 Canada viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 17 Canada viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 18 Europe viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
• Table 19 Europe viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 20 Europe viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 21 Europe viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 22 Europe viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 23 Europe viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 24 UK viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 25 UK viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 26 UK viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 27 UK viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 28 UK viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 29 Germany viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 30 Germany viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 31 Germany viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 32 Germany viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 33 Germany viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 34 France viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 35 France viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 36 France viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 37 France viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 38 France viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 39 Spain viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 40 Spain viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 41 Spain viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 42 Spain viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 43 Spain viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 44 Italy viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 45 Italy viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 46 Italy viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 47 Italy viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 48 Italy viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 49 Denmark viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 50 Denmark viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 51 Denmark viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 52 Denmark viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 53 Denmark viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 54 Sweden viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 55 Sweden viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 56 Sweden viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 57 Sweden viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 58 Sweden viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 59 Norway viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 60 Norway viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 61 Norway viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 62 Norway viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 63 Norway viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 67 Asia Pacific viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 68 Asia Pacific viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 70 Japan viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 71 Japan viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 72 Japan viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 73 Japan viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 74 Japan viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 75 China viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 76 China viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 77 China viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 78 China viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 79 China viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 80 India viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 81 India viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 82 India viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 83 India viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 84 India viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 85 South Korea viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 86 South Korea viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 87 South Korea viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 88 South Korea viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 89 South Korea viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 90 Australia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 91 Australia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 92 Australia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 93 Australia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 94 Australia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 95 Thailand viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 96 Thailand viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 97 Thailand viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 98 Thailand viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 99 Thailand viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 100 Latin America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
• Table 101 Latin America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 102 Latin America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 103 Latin America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 104 Latin America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 105 Latin America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 106 Brazil viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 107 Brazil viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 108 Brazil viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 109 Brazil viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 110 Brazil viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 111 Mexico viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 112 Mexico viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 113 Mexico viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 114 Mexico viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 115 Mexico viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 116 Argentina viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 117 Argentina viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 118 Argentina viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 119 Argentina viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 120 Argentina viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 121 Middle East and Africa viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
• Table 122 Middle East and Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 123 Middle East and Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 124 Middle East and Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 125 Middle East and Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 126 Middle East and Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 127 South Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 128 South Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 129 South Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 130 South Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 131 South Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 133 Saudi Arabia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 134 Saudi Arabia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 136 Saudi Arabia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 137 UAE viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 138 UAE viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 139 UAE viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 140 UAE viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 141 UAE viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
• Table 142 Kuwait viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
• Table 143 Kuwait viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
• Table 144 Kuwait viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 145 Kuwait viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
• Table 146 Kuwait viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Viral vector and plasmid DNA manufacturing market: market outlook
• Fig. 9 Viral vector and plasmid DNA manufacturing competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Viral vector and plasmid DNA manufacturing market driver impact
• Fig. 15 Viral vector and plasmid DNA manufacturing market restraint impact
• Fig. 16 Viral vector and plasmid DNA manufacturing market strategic initiatives analysis
• Fig. 17 Viral vector and plasmid DNA manufacturing market: Vector type movement analysis
• Fig. 18 Viral vector and plasmid DNA manufacturing market: Vector type outlook and key takeaways
• Fig. 19 Adenovirus market estimates and forecast, 2018 - 2030
• Fig. 20 Retrovirus market estimates and forecast, 2018 - 2030
• Fig. 21 Adeno-Associated Virus (AAV)market estimates and forecast, 2018 - 2030
• Fig. 22 Lentivirus market estimates and forecast, 2018 - 2030
• Fig. 23 Plasmids market estimates and forecast, 2018 - 2030
• Fig. 24 Others market estimates and forecast, 2018 - 2030
• Fig. 25 Viral vector and plasmid DNA manufacturing market: Workflow movement Analysis
• Fig. 26 Viral vector and plasmid DNA manufacturing market: Workflow outlook and key takeaways
• Fig. 27 Upstream manufacturing market estimates and forecasts, 2018 - 2030
• Fig. 28 Vector amplification & expansion market estimates and forecasts, 2018 - 2030
• Fig. 29 Vector recovery/harvesting market estimates and forecasts, 2018 - 2030
• Fig. 30 Downstream manufacturing market estimates and forecasts, 2018 - 2030
• Fig. 31 Purification market estimates and forecasts, 2018 - 2030
• Fig. 32 Fill finish market estimates and forecasts, 2018 - 2030
• Fig. 33 Viral vector and plasmid DNA manufacturing market: Application movement Analysis
• Fig. 34 Viral vector and plasmid DNA manufacturing market: Application outlook and key takeaways
• Fig. 35 Antisense & RNAi therapy market estimates and forecasts, 2018 - 2030
• Fig. 36 Gene Therapy market estimates and forecasts, 2018 - 2030
• Fig. 37 Cell Therapy market estimates and forecasts, 2018 - 2030
• Fig. 38 Vaccinology market estimates and forecasts, 2018 - 2030
• Fig. 39 Research Applications market estimates and forecasts, 2018 - 2030
• Fig. 40 Viral vector and plasmid DNA manufacturing market: End-use movement Analysis
• Fig. 41 Viral vector and plasmid DNA manufacturing market: End-use outlook and key takeaways
• Fig. 42 Pharmaceutical and biopharmaceutical companies market estimates and forecasts, 2018 - 2030
• Fig. 43 Research institutes market estimates and forecasts, 2018 - 2030
• Fig. 44 Viral vector and plasmid DNA manufacturing market: Disease movement Analysis
• Fig. 45 Viral vector and plasmid DNA manufacturing market: Disease outlook and key takeaways
• Fig. 46 Cancer market estimates and forecasts, 2018 - 2030
• Fig. 47 Genetic disorders market estimates and forecasts, 2018 - 2030
• Fig. 48 Infectious Diseases market estimates and forecasts, 2018 - 2030
• Fig. 49 Others market estimates and forecasts, 2018 - 2030
• Fig. 50 Global viral vector and plasmid DNA manufacturing market: Regional movement analysis
• Fig. 51 Global viral vector and plasmid DNA manufacturing market: Regional outlook and key takeaways
• Fig. 52 Global viral vector and plasmid DNA manufacturing market share and leading players
• Fig. 53 North America, by country
• Fig. 54 North America
• Fig. 55 North America market estimates and forecasts, 2018 - 2030
• Fig. 56 U.S.
• Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 58 Canada
• Fig. 59 Canada market estimates and forecasts, 2018 - 2030
• Fig. 60 Europe
• Fig. 61 Europe market estimates and forecasts, 2018 - 2030
• Fig. 62 UK
• Fig. 63 UK market estimates and forecasts, 2018 - 2030
• Fig. 64 Germany
• Fig. 65 Germany market estimates and forecasts, 2018 - 2030
• Fig. 66 France
• Fig. 67 France market estimates and forecasts, 2018 - 2030
• Fig. 68 Italy
• Fig. 69 Italy market estimates and forecasts, 2018 - 2030
• Fig. 70 Spain
• Fig. 71 Spain market estimates and forecasts, 2018 - 2030
• Fig. 72 Denmark
• Fig. 73 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 74 Sweden
• Fig. 75 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 76 Norway
• Fig. 77 Norway market estimates and forecasts, 2018 - 2030
• Fig. 78 Asia Pacific
• Fig. 79 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 80 China
• Fig. 81 China market estimates and forecasts, 2018 - 2030
• Fig. 82 Japan
• Fig. 83 Japan market estimates and forecasts, 2018 - 2030
• Fig. 84 India
• Fig. 85 India market estimates and forecasts, 2018 - 2030
• Fig. 86 Thailand
• Fig. 87 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 88 South Korea
• Fig. 89 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 90 Australia
• Fig. 91 Australia market estimates and forecasts, 2018 - 2030
• Fig. 92 Latin America
• Fig. 93 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 94 Brazil
• Fig. 95 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 96 Mexico
• Fig. 97 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 98 Argentina
• Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 100 Middle East and Africa
• Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 102 South Africa
• Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 104 Saudi Arabia
• Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 106 UAE
• Fig. 107 UAE market estimates and forecasts, 2018 - 2030
• Fig. 108 Kuwait
• Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 110 Market share of key market players- Viral vector and plasmid DNA manufacturing market

Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends:

The global viral vector and plasmid DNA manufacturing market size is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.

With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.

Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.

Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.

Viral Vector And Plasmid DNA Manufacturing Market Report Highlights:

• Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20.0% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
• Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
• Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
• Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
• In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
• North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Vector type
  • 1.2.2. Workflow
  • 1.2.3. Application
  • 1.2.4. End-use
  • 1.2.5. Disease
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
    • 3.2.1.2. Technological Advancements in Manufacturing Vectors
    • 3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
• 3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis

• 4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
• 4.2. Adeno-associated virus (AAV)
  • 4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.3. Lentivirus
  • 4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.4. Adenovirus
  • 4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.5. Retrovirus
  • 4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.6. Plasmids
  • 4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis

• 5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
• 5.2. Upstream Manufacturing
  • 5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.2.2. Vector Amplification & Expansion
    • 5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.2.3. Vector Recovery/Harvesting
    • 5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 5.3. Downstream Manufacturing
  • 5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.3.2. Purification
    • 5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.3.3. Fill Finish diagnostic instruments
    • 5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis

• 6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
• 6.2. Gene Therapy
  • 6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 6.3. Cell Therapy
  • 6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 6.4. Vaccinology
  • 6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 6.5. Research Applications
  • 6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis

• 7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
• 7.2. Pharmaceutical and Biopharmaceutical Companies
  • 7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 7.3. Research Institutes
  • 7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis

• 8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
• 8.2. Cancer
  • 8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 8.3. Genetic Disorders
  • 8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 8.4. Infectious Diseases
  • 8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 8.5. Other
  • 8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. North America
  • 9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. Regulatory framework
    • 9.2.2.3. Competitive scenario
    • 9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.2.2.5. Target disease prevalence
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Regulatory framework
    • 9.2.3.3. Competitive scenario
    • 9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.2.3.5. Target disease prevalence
• 9.3. Europe
  • 9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.2.5. Target disease prevalence
  • 9.3.3. Germany
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.3.5. Target disease prevalence
  • 9.3.4. France
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive scenario
    • 9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.4.5. Target disease prevalence
  • 9.3.5. Italy
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. Regulatory framework
    • 9.3.5.3. Competitive scenario
    • 9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.5.5. Target disease prevalence
  • 9.3.6. Spain
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Regulatory framework
    • 9.3.6.3. Competitive scenario
    • 9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.6.5. Target disease prevalence
  • 9.3.7. Norway
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Regulatory framework
    • 9.3.7.3. Competitive scenario
    • 9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.7.5. Target disease prevalence
  • 9.3.8. Sweden
    • 9.3.8.1. Key country dynamics
    • 9.3.8.2. Regulatory framework
    • 9.3.8.3. Competitive scenario
    • 9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.8.5. Target disease prevalence
  • 9.3.9. Denmark
    • 9.3.9.1. Key country dynamics
    • 9.3.9.2. Regulatory framework
    • 9.3.9.3. Competitive scenario
    • 9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.9.5. Target disease prevalence
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.2.5. Target disease prevalence
  • 9.4.3. China
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.3.5. Target disease prevalence
  • 9.4.4. India
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.4.5. Target disease prevalence
  • 9.4.5. Australia
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.5.5. Target disease prevalence
  • 9.4.6. South Korea
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.6.5. Target disease prevalence
  • 9.4.7. Thailand
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.7.5. Target disease prevalence
• 9.5. Latin America
  • 9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.2.5. Target disease prevalence
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.3.5. Target disease prevalence
  • 9.5.4. Argentina
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.4.5. Target disease prevalence
• 9.6. MEA
  • 9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.2.5. Target disease prevalence
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.3.5. Target disease prevalence
  • 9.6.4. UAE
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.4.5. Target disease prevalence
  • 9.6.5. Kuwait
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.5.5. Target disease prevalence

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2023
• 10.4. Company Profiles/Listing
  • 10.4.1. Merck KGaA
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Lonza
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. FUJIFILM Diosynth Biotechnologies
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Thermo Fisher Scientific
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Cobra Biologics
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Catalent Inc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Wuxi Biologics
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Takara Bio Inc.
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Waisman Biomanufacturing
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Genezen laboratories
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Batavia Biosciences
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. Miltenyi Biotec GmbH
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product benchmarking
    • 10.4.12.4. Strategic initiatives
  • 10.4.13. SIRION Biotech GmbH
    • 10.4.13.1. Company overview
    • 10.4.13.2. Financial performance
    • 10.4.13.3. Product benchmarking
    • 10.4.13.4. Strategic initiatives
  • 10.4.14. Virovek Incorporation
    • 10.4.14.1. Company overview
    • 10.4.14.2. Financial performance
    • 10.4.14.3. Product benchmarking
    • 10.4.14.4. Strategic initiatives
  • 10.4.15. BioNTech IMFS GmbH
    • 10.4.15.1. Company overview
    • 10.4.15.2. Financial performance
    • 10.4.15.3. Product benchmarking
    • 10.4.15.4. Strategic initiatives
  • 10.4.16. Audentes Therapeutics
    • 10.4.16.1. Company overview
    • 10.4.16.2. Financial performance
    • 10.4.16.3. Product benchmarking
    • 10.4.16.4. Strategic initiatives
  • 10.4.17. BioMarin Pharmaceutical
    • 10.4.17.1. Company overview
    • 10.4.17.2. Financial performance
    • 10.4.17.3. Product benchmarking
    • 10.4.17.4. Strategic initiatives
  • 10.4.18. RegenxBio, Inc.
    • 10.4.18.1. Company overview
    • 10.4.18.2. Financial performance
    • 10.4.18.3. Product benchmarking
    • 10.4.18.4. Strategic initiatives